PURPOSE: To evaluate the subsequent risk of @entity1031 in @entity1 receiving intravitreal ranibizumab and bevacizumab for age-related @entity1020 or macular @entity4 . DESIGN: Population-based crossover analysis with self-matched historical control data. METHODS: setting: Ontario, Canada, between April 1, 2006, and March 31, 2013. STUDY POPULATION: Consecutive @entity1 65 and older who initiated intravitreal treatment (N  = 57 919). INTERVENTION: Intravitreal injection of ranibizumab or bevacizumab. MAIN OUTCOME MEASURES: Emergency visits for @entity1031 spanning 1-4 years before treatment were compared to 1 year after treatment. Also examined were other secondary events including @entity173 , @entity712 , @entity951 , falls, @entity308 , @entity2679 , and total emergencies, as well as a control group following @entity231 surgery. RESULTS: A total of 57 919 @entity1 were included who accounted for 1858 @entity1031 emergencies (48 per month) during the 3-year Baseline interval and 1077 @entity1031 emergencies (83 per month) during the 1-year Subsequent interval after initiating treatment. The absolute change in risk equaled an increase from 10.7 to 18.6 per 1000 @entity1 annually after initiation of treatment (rate ratio 1.74; 95% confidence interval 1.58-1.92; P < .0001). The relative increase was particularly pronounced for @entity385 (rate ratio 2.18; 95% confidence interval 1.94-2.46; P < .0001). The observed increase exceeded trends due to aging, applied across @entity1 with diverse characteristics, occurred with each medication (ranibizumab and bevacizumab), was not apparent for emergencies unrelated to @entity1031 , and did not occur in a control group following @entity231 surgery. CONCLUSIONS: Intravitreal anti- @entity7 medications ranibizumab and bevacizumab may contribute to systemic @entity1031 in @entity1  aged 65 years or older.

Intravitreal anti- @entity7 treatment and the risk of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depression'] @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor'] @entity4 :: ('MESH:D004487', 'Disease') :: ['edema'] @entity173 :: ('MESH:D006620', 'Disease') :: ['hip fractures'] @entity951 :: ('MESH:D000787', 'Disease') :: ['angina'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic', 'thromboembolic events'] @entity2679 :: ('MESH:D002764', 'Disease') :: ['cholecystitis'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['macular degeneration'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity1031 :: (MESH:D013923,Disease) :: ['thromboembolism']
